Multifactorial Involvement of Multidrug Resistance Protein, DNA Topoisomerase II and Glutathione/Glutathione-S-Transferase in NonP- Glycoprotein-Mediated Multidrug Resistance in Human Bladder Cancer Cells
- 1 November 1997
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 4 (6) , 583-590
- https://doi.org/10.1111/j.1442-2042.1997.tb00314.x
Abstract
Multiple mechanisms are important in multidrug resistance in urothelial cancers. We investigated the acquisition of a multidrug resistance phenotype in human bladder cancer cells exposed to doxorubicin. Human bladder cancer cell line 5637 and 2 doxorubicin drug-resistant sublines (5637/DR5.5 and 5637/DR50) were used. Measurements were made of the steady state mRNA levels of the multidrug resistance gene (mdr1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi and DNA topoisomerase II (topo II) genes, P-glycoprotein (PgP) and MRP expression, glutathione (GSH) and GSH enzyme activity, and topo II catalytic activity. The pharmacokinetics were compared between the parent and the drug-resistant sublines. 5637/DR5.5 and 5637/DR50 cells were 7.6- and 16.2-fold more resistant to doxorubicin and 16.7- and 48.3-fold more resistant to etoposide, respectively, compared with 5637 cells. A dose escalation of doxorubicin increased the MRP expression, GSH levels and glutathione-S-transferase (GST) activity, although no PgP expression was observed in any cell line. Resistance was brought about by decreased drug accumulation through drug efflux, although intracellular daunorubicin concentrations were similar between DR5.5 and DR50 cells. Topo II catalytic activity was undetectable in DR50 cells, but maintained in both the parent and DR5.5 cells. Reduced drug accumulation in doxorubicin-resistant cells was mediated by MRP instead of PgP indicating that MRP-mediated drug efflux functions in a limited manner for drug resistance. An increase in drug efflux via MRP, reduced topo II activity, and increased GSH levels/GSH-related enzyme activities may play major roles in nonPgP-mediated multidrug resistance in urothelial cancers treated with anthracyclines.Keywords
This publication has 14 references indexed in Scilit:
- Expression of multidrug resistance‐related genes (mdrl, MRP, GST‐πand DNA topoisomerase II) in urothelial cancersBritish Journal of Urology, 1996
- Expression Patterns Of Multidrug-Resistance (MDR1), Multidrug Resistance-Associated Protein (MRP), Glutathione-S-Transferase-pi (GST-pi) and DNA Topoisomerase II (TOPO II) Genes In Renal Cell Carcinomas And Normal KidneyJournal of Urology, 1996
- Multidrug Resistance-associated Protein-mediated Multidrug Resistance Modulated by Cyclosporin A in a Human Bladder Cancer Cell LineJapanese Journal of Cancer Research, 1995
- Reversal by a Dihydropyridine Derivative of Non-P-Glycoprotein-Mediated Multidrug Resistance in Etoposide-Resistant Human Prostatic Cancer Cell LineJournal of Urology, 1995
- A study of the mechanism of resistance to Adriamycin® in vivoBiochemical Pharmacology, 1989
- Role of the Glutathione Redox Cycle in Acquired and de Novo Multidrug ResistanceScience, 1988
- Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistanceNature, 1986
- Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cellsCell, 1986
- Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletionBiochemical Pharmacology, 1985
- Selective Modification of Glutathione MetabolismScience, 1983